Policy support accelerates the advancement of innovative drug R&D.
Release time:
2024-05-13
Recently, the General Office of the State Council issued the "Opinions on Comprehensively Deepening the Reform of Drug and Medical Device Regulation and Promoting High-Quality Development of the Pharmaceutical Industry," injecting strong momentum into the development of the pharmaceutical industry.
Recently, the General Office of the State Council issued the "Opinions on Comprehensively Deepening the Reform of Drug and Medical Device Regulation and Promoting High-Quality Development of the Pharmaceutical Industry," injecting strong momentum into the development of the pharmaceutical sector. The Opinions clearly state that by 2027, a regulatory system aligned with pharmaceutical innovation and industrial development will be established, and review and approval resources will be increasingly tilted toward urgently needed, innovative drugs for clinical use. Throughout the entire process—from clinical trials to registration applications—regulatory authorities will strengthen communication and engagement with pharmaceutical companies and provide tailored guidance. The introduction of this policy has greatly boosted the confidence of innovative pharmaceutical companies. For instance, Hengrui Medicine’s independently developed darolutamide hydrochloride tablets, in combination with endocrine therapy, achieved a major breakthrough in the Phase III clinical trial for adjuvant treatment of HR-positive/HER2-negative breast cancer, significantly reducing the risk of recurrence. With policy support combined with corporate innovation, it is expected that more innovative drugs will accelerate their launch in the future, offering patients an even wider range of treatment options.
Address: 6th Floor, Building C6, Jiangsu Life Science and Technology Innovation Park, Qixia District, Nanjing City
Official account